



PTO/SB/08A/B (09-03)

Approved for use through 03/31/2007. OMB 0651-0231

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	64348(41925)
-------	---	----	---	------------------------	--------------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
AA	US-3,184,462		05/18/1965	Scarborough et al.	
AB	US-5,250,544		10/05/1993	Lavieille et al.	
AC	US-5,747,502		05/05/1998	Hanacka et al.	
AD	US-6,046,206		04/04/2000	Pamukcu et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number-Kind Code ⁴ (if known)	MM-DD-YYYY		
BA	WO 96/39145 A1		12/12/1996	Rhone-Poulenc Rorer Pharmaceuticals Inc.	
BB	WO 99/10442 A1		01/14/1999	Zeneca Limited	
BC	WO 99/48461 A2		09/30/1999	Department of the Army	
BD	WO 00/77848 A1		12/28/2000	Smithkline Beecham P.L.C.	
BE	WO 01/07432 A2		02/01/2001	Smithkline Beecham P.L.C.	
BF	WO 01/10842 A2		02/15/2001	Millennium Pharmaceuticals, Inc.	
BG	WO 01/46150 A2		06/28/2001	Globo Group Limited	
BH	WO 02/08224 A1		01/31/2002	Smithkline Beecham P.L.C.	
BI	WO 02/40474 A2		05/23/2002	Aventis Pharma S.A.	
BJ	WO 02/056882 A1		07/25/2002	Smithkline Beecham P.L.C.	
BK	WO 02/072572 A1		09/19/2002	Aventis Pharma S.A.	
BL	WO 03/064421 A1		08/07/2003	Globo Group Limited	
BM	WO 03/087098 A1		10/23/2003	Smithkline Beecham P.L.C.	
BN	WO 2004/002992 A1		01/08/2004	Globo Group Limited	
BO	WO 2004/035569 A2		04/29/2004	Morphochem Aktiengesellschaft Für Kombinatorische Chemie	
BP	WO 2004/058144 A2		07/15/2004	Globo Group Limited	
BQ	WO 2006/021448 A1		03/02/2006	Morphochem Aktiengesellschaft Für Kombinatorische Chemie	
BR	JP 6120054 (w/abstract)		09/05/1986	Tosay Ink Mfg. Co.	
BS	EP 0 042 781 B1 (w/abstract)		03/06/1985	Pharmuka Laboratories	
BT	EP 0 264 883 A2		04/27/1988	Banyu Pharmaceutical Co., Ltd.	
BU	EP 0 486 022 B1		05/20/1992	Eisai Co., Ltd.	
BV	EP 0 737 670 B1 (w/abstract)		10/16/1996	Adir et Compagnie	
BW	DE 102 47 233 A1 (w/abstract)		06/17/2004	Morphochem Aktiengesellschaft Für Kombinatorische Chemie	
BX	DE 102 56 405 A1 (w/abstract)		06/17/2004	Morphochem Aktiengesellschaft Für Kombinatorische Chemie	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 596561	Rebecca Anderson	Date Considered 01/21/2009
------------------------------	------------------	-------------------------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RA/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	64348(41925)
-------	---	----	---	------------------------	--------------

NON PATENT LITERATURE DOCUMENTS

Examiner initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CA	Chemical Abstract – Wei et al.; "A practical procedure for multisubstituted .beta.-naphthols and their derivatives" <i>Tetrahedron</i> , 59(34), 2003, pp. 6621-6625.		
CB	Chemical Abstract – Harayama et al.; "Novel synthesis of naphthobenzazepines from N-bromobenzylnaphthyrimidines by regioselective C-H activation utilizing the intramolecular coordination of an amine to Pd"; <i>Synlett</i> , (8), 2003, pp. 1141-1144.		
CC	Chemical Abstract – Nagy et al.; "Theoretical and Experimental Study on Ion-Pair Formation and partitioning of organic Salts in Octano/Water and Dichloromethane/Water Systems"; <i>Journal of the America Chemical Society</i> ; 122 (28), 2000, pp. 6583-6593.		
CD	Chemical Abstract – Moehrle et al.; "1,2,3,4-Tetrahydroquinolines as substrates for Mannich compounds"; <i>Zeitschrift fuer Naturforschung, B: Chemical Sciences</i> ; 53(7), 1998, pp. 742-752.		
CE	Chemical Abstract – Mathe-Alainmat et al.; "Synthesis of 2-Amido-2,3-dihydro-1H-phenalen Derivatives as New Conformationally Restricted Ligands for Melanotonin Receptors"; <i>Journal of Medicinal Chemistry</i> ; 39 (16), 1996, pp. 3089-3095.		
CF	Chemical Abstract – Iwasaki et al.; "Novel Selective PDE IV Inhibitors as Antiallergic Agents. Synthesis and Biological Activities of a Series of 1-Aryl-2,3-bis(hydroxymethyl) naphthalene Ligands"; <i>Journal of Medicinal Chemistry</i> , 39(14), 1996, pp. 2696-2704.		
CG	Chemical Abstract – Zhang et al.; "Organic reactions in chiral micelles. 7. The structural effects on the asymmetric oxidation of prochiral Sulfides in chiral micelles"; <i>Chinese Journal of Chemistry</i> , (1), 1990, pp. 89-95.		
CH	Chemical Abstract – Smidrkal, Jan; "Synthesis of fagorone"; <i>Collection of Czechoslovak Chemical Communications</i> ; 53(12), 1998, pp. 3184-3192.		
CI	Chemical Abstract – Fleischhacker et al.; "Heterocyclic fused naphthalene systems from thebaine. 1"; <i>Liebigs Annalen der Chemie</i> , (5), 1983, pp. 844-851.		
CJ	Chemical Abstract – Budzikiewicz et al.; "Vincetoxine, a benzopyrrolisoquinoline alkaloid, from <i>Cynanchum Vincetoxicum</i> (L.) Pers. (<i>Asclepiadaceae</i>)"; <i>Liebigs Annalen der Chemie</i> (8), 1979, pp. 1212-1231.		
CK	Chemical Abstract – Frost et al.; "Naturally occurring compounds related to phenalenone. V. Synthetic approaches to structures based on 8,9-dihydro-8,8,9-trimethylphenalen-1[2-b]-furan-7-one"; <i>Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</i> ; (19), 1973, pp. 3159-2169.		
CL	Chemical Abstract – Jorgensen et al.; "Thyroxine analogs. 20. Substituted 1- and 2-naphthyl ethers of 3,5-diiodotyrosine"; <i>Journal of Medicinal Chemistry</i> , 14(11), 1971, pp. 1023-1026.		
CM	Chemical Abstract – Kasturi et al.; "Reactions of tetrabromo-1,2-benzoquinones. III. Reaction of tetrachloro-1,2-benzoquinone with tetralones and naphthols; pathway to the condensates"; <i>Journal of the Chemical Society [Section] C: Organic</i> , (9), 1970, pp. 1257-1259.		
CN	Chemical Abstract – Harada et al.; "Structure of pristimerin, a quinonoid triterpene"; <i>Tetrahedron Letters</i> , 1962, pp. 603-607.		

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 969360	Rebecca Anderson	Date Considered 01/21/2009
------------------------------	------------------	-------------------------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RA/